Evidence map›Paper›PMID 39535430›Full record

ArticleNano letters2024

Cellular Nanoparticles Treat Coronavirus Infection

Yiyan Yu, Daniela Silva-Ayala, Zhidong Zhou, Yifei Peng, Ronnie H Fang, Weiwei Gao, Anthony Griffiths, Liangfang Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nano letters, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Intelligent Programmable Membrane Nanosponge for Early Virus Blocking.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. An Off-the-Shelf Artificial Proregenerative Macrophage for Pressure Ulcer Treatment.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yiyan YuAiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0002-7136-654X
Daniela Silva-AyalaDepartment of Microbiology and National Emerging Infectious Diseases Laboratories, School of Medicine, Boston University, Boston, Massachusetts 02115, United States.
Zhidong ZhouAiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San Diego, La Jolla, California 92093, United States.
Yifei PengAiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San Diego, La Jolla, California 92093, United States.
Ronnie H FangAiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0001-6373-3189
Weiwei GaoAiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0001-5196-4887
Anthony GriffithsDepartment of Microbiology and National Emerging Infectious Diseases Laboratories, School of Medicine, Boston University, Boston, Massachusetts 02115, United States.
Liangfang ZhangAiiso Yufeng Li Family Department of Chemical and Nano Engineering, Shu and K.C. Chien and Peter Farrell Collaboratory, University of California San Diego, La Jolla, California 92093, United States.ORCID 0000-0003-0637-0654

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cellular nanoparticles (CNPs), which refer to nanoparticles coated with natural cell membranes, are promising for neutralizing pathological agents. Here, we use CNPs as a medical countermeasure against the infection of SARS-CoV-2 variants in an animal model. CNPs comprise polymeric cores coated with the plasma membranes of human macrophages. The resulting nanoparticles (MΦ-NPs) act as host cell decoys to intercept SARS-CoV-2 and block its cellular entry, thus inhibiting subsequent viral infection. Our findings indicate that MΦ-NPs bind to the spike proteins of SARS-CoV-2 variants in a dose-dependent manner and inhibit the infectivity of live viruses. In hamsters infected with SARS-CoV-2 variants, MΦ-NPs significantly reduce the viral burden in the lungs, demonstrating their effectiveness in inhibiting viral infectivity

Indexed as

COVID-19NanoparticlesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsAntiviral AgentsChlorocebus aethiopsCOVID-19 Drug TreatmentCricetinaeDisease Models, AnimalHumansLungMacrophagesMacrophages, AlveolarVero CellsVirus InternalizationAntiviral AgentsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antiviralbiological neutralizationcell membrane coatingcellular nanoparticlecoronavirus

Identifiers

PMID39535430
PMCPMC11613681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.